Selskabsmeddelelse

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2025

13.12.2024, 12.00

BBS-Bioactive Bone Substitutes Plc | Company Release | December 13, 2024 at 13:00:00 EET

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2025

BBS-Bioactive Bone Substitutes Plc (“BBS”) will publish its financial reports for 2025 as follows:

Report	Date
Financial statements release for 2024	February 21, 2025
Annual report 2024	Week commencing on March 17, 2025
Half-year report January – June, 2025	August 29, 2025

BBS-Bioactive Bone Substitutes Plc observes a silent period before publishing financial reports. The silent period preceding the publication of the financial statement release is four weeks.

The Annual General Meeting of BBS-Bioactive Bone Substitutes Plc is scheduled to be held on Tuesday, April 29, 2025. The Board of Directors will convene the Annual General Meeting separately later.

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi